AI Earnings Predictions for McKesson Corporation (MCK)

mck-202602040000927653false00009276532026-02-042026-02-040000927653us-gaap:CommonStockMember2026-02-042026-02-040000927653mck:A1.625NotesDue2026Member2026-02-042026-02-040000927653mck:A3.125NotesDue2029Member2026-02-042026-02-04

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 4, 2026

McKESSON CORPORATION (Exact Name of Registrant as Specified in Charter)

Delaware1-1325294-3207296 (State or Other Jurisdiction of Incorporation)(Commission File Number)(I.R.S. Employer Identification No.)

6555 State Hwy 161 Irving, TX 75039 (Address of Principal Executive Offices, and Zip Code) (972) 446-4800 Registrant’s Telephone Number, Including Area Code Not Applicable (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading Symbol(s)Name of each exchange on which registered Common stock, $0.01 par valueMCKNew York Stock Exchange

1.625% Notes due 2026MCK26New York Stock Exchange 3.125% Notes due 2029MCK29New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company  ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

Item 2.02     Results of Operations and Financial Condition. On February 4, 2026, McKesson Corporation (the “Company”) reported the Company’s preliminary results for the quarter ended on December 31, 2025 which are attached hereto as Exhibit 99.1. The information contained in this Form 8-K, including Exhibit 99.1, is furnished to the Securities and Exchange Commission (the “Commission”), but shall not be deemed “filed” with the Commission for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act except as shall be expressly set forth by specific reference in such a filing. Item 9.01     Financial Statements and Exhibits. (d) Exhibits.

Exhibit No.  Description

99.1   Earnings release issued by the Company dated February 4, 2026

104 Cover Page Interactive Data File - the cover page iXBRL tags are embedded within the Inline XBRL document

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: February 4, 2026

McKesson Corporation

By:/s/ Britt J. Vitalone Britt J. Vitalone Executive Vice President and Chief Financial Officer

mck-202511050000927653false00009276532025-11-052025-11-050000927653us-gaap:CommonStockMember2025-11-052025-11-050000927653mck:A1.500NotesDue2025Member2025-11-052025-11-050000927653mck:A1.625NotesDue2026Member2025-11-052025-11-050000927653mck:A3.125NotesDue2029Member2025-11-052025-11-05

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 5, 2025

McKESSON CORPORATION (Exact Name of Registrant as Specified in Charter)

Delaware1-1325294-3207296 (State or Other Jurisdiction of Incorporation)(Commission File Number)(I.R.S. Employer Identification No.)

6555 State Hwy 161 Irving, TX 75039 (Address of Principal Executive Offices, and Zip Code) (972) 446-4800 Registrant’s Telephone Number, Including Area Code Not Applicable (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading Symbol(s)Name of each exchange on which registered Common stock, $0.01 par valueMCKNew York Stock Exchange

1.500% Notes due 2025MCK25New York Stock Exchange 1.625% Notes due 2026MCK26New York Stock Exchange 3.125% Notes due 2029MCK29New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company  ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

Item 2.02     Results of Operations and Financial Condition. On November 5, 2025, McKesson Corporation (the “Company”) reported the Company’s preliminary results for the quarter ended on September 30, 2025 which are attached hereto as Exhibit 99.1. The information contained in this Form 8-K, including Exhibit 99.1, is furnished to the Securities and Exchange Commission (the “Commission”), but shall not be deemed “filed” with the Commission for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act except as shall be expressly set forth by specific reference in such a filing. Item 9.01     Financial Statements and Exhibits. (d) Exhibits.

Exhibit No.  Description

99.1   Earnings release issued by the Company dated November 5, 2025

104 Cover Page Interactive Data File - the cover page iXBRL tags are embedded within the Inline XBRL document

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: November 5, 2025

McKesson Corporation

By:/s/ Britt J. Vitalone Britt J. Vitalone Executive Vice President and Chief Financial Officer

mck-2025091800009276538-K09/18/2025false00009276532025-09-182025-09-180000927653us-gaap:CommonStockMember2025-09-182025-09-180000927653mck:A1.500NotesDue2025Member2025-09-182025-09-180000927653mck:A1.625NotesDue2026Member2025-09-182025-09-180000927653mck:A3.125NotesDue2029Member2025-09-182025-09-18

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 18, 2025

McKESSON CORPORATION (Exact Name of Registrant as Specified in Charter)

Delaware1-1325294-3207296 (State or Other Jurisdiction of Incorporation)(Commission File Number)(I.R.S. Employer Identification No.)

6555 State Hwy 161 Irving, TX 75039 (Address of Principal Executive Offices, and Zip Code) (972) 446-4800 Registrant’s Telephone Number, Including Area Code Not Applicable (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading Symbol(s)Name of each exchange on which registered Common stock, $0.01 par valueMCKNew York Stock Exchange 1.500% Notes due 2025MCK25New York Stock Exchange 1.625% Notes due 2026MCK26New York Stock Exchange 3.125% Notes due 2029MCK29New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company  ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

Item 2.02 Results of Operations and Financial Condition.

The information set forth in Item 8.01 is incorporated herein by reference.

Item 8.01 Other Events

Commencing in the second quarter of fiscal 2026, McKesson Corporation (the “Company,” “McKesson,” “we,” “our,” and other similar pronouns) will report financial results across four reportable segments: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions. Our Norwegian operations will be included in Other. The organizational structure also includes Corporate, which consists of income and expenses associated with administrative functions and projects, and the results of certain investments. These segment changes reflect how our Chief Executive Officer, who is our chief operating decision maker, allocates resources and assesses performance beginning in the second quarter of fiscal 2026. The segment changes did not impact our previously issued consolidated financial statements or our historical earnings per diluted share. Additional information regarding our reportable segments is as follows: •North American Pharmaceutical: A newly defined reportable segment combining McKesson’s scaled wholesale drug distribution businesses in the United States and Canada. It delivers best-in-class distribution services to a broad customer base, including retail and community pharmacies, and institutional healthcare providers. •Oncology & Multispecialty: A newly defined reportable segment that includes a portfolio of integrated solutions across oncology and multispecialty providers and solutions. The segment includes specialty provider solutions, including distribution-related capabilities, such as specialty drug distribution and group purchasing organizations; and Practice management services supporting the largest physician-led, community-based oncology networks. The segment also includes other multispecialty providers, including retina and ophthalmology, and offers clinical trial services, specialty pharmacy solutions, and access to cutting-edge research, along with innovation through technology-driven insights. •Prescription Technology Solutions: Connects patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma through scaled and differentiated networks, improving medication access and affordability, while delivering measurable value to biopharma. •Medical-Surgical Solutions: Delivers medical-surgical supply distribution, logistics, and other related services to healthcare providers across alterna